Parkwoods Wealth Partners’s Akebia Therapeutics AKBA Stock Holding History

Parkwoods Wealth Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Buy	21,038 +38	+0.2%	+$45	﹤0.01%	167
2026 Q1	$29.2K	Buy	21,000 +1,000	+5%	+$1.37K	0.01%	109
2025 Q4	$32.2K	Hold	20,000	–	–	0.01%	107
2025 Q3	$54.6K	Buy	+20,000	New	+$66.5K	0.02%	94

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

UIM

Unified Investment Management Atlanta, Georgia $108M AUM 26.38% 1-Year Est. Return

Parkwoods Wealth Partners's AKBA Position: Q2 2026 in Review

Parkwoods Wealth Partners increased its Akebia Therapeutics (AKBA) stake by 0.18% in Q2 2026, buying an estimated $45 and bringing the position to 21,038 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #167.

Parkwoods Wealth Partners first reported a position in AKBA in Q3 2025 and has held it in 4 quarters since. The position peaked at $54.6K in Q3 2025. 27 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Parkwoods Wealth Partners held 21,038 shares of Akebia Therapeutics worth $24K as of Q2 2026.
Parkwoods Wealth Partners bought 38 Akebia Therapeutics shares in Q2 2026, an estimated $45.
Akebia Therapeutics made up ﹤0.01% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #167 holding.
Parkwoods Wealth Partners first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 4 quarters since.
Parkwoods Wealth Partners's Akebia Therapeutics position peaked at $54.6K in Q3 2025.
27 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.